Clinical trials: Acute Coronary Event
Unexpected Hospital Mortality, Death, Sudden, Cardiac
Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.
1. Summary Growing evidence suggests that a significant proportion of in-hospital patient deaths occur after serious adverse events (SAE's).
- Conditions
- Unexpected Hospital Mortality, Death, Sudden, Cardiac, Unplanned Intensive Care Unit Admission
- Trial name
- ALARM (NCT01949025)
- Testing
- ALARM intervention
- Where
- Belgium
- Volunteers
- 69,656 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Type2 Diabetes Mellitus, Microangiopathy
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke).
- Conditions
- Type2 Diabetes Mellitus, Microangiopathy, Non Alcoholic Fatty Liver Disease, Coronary Artery Disease
- Trial name
- PRECISED (NCT02248311)
- Where
- Spain
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hypercholesterolemia
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
- Trial name
- LAMISIII (NCT04270344)
- Testing
- Pitavastatin 4mg
- Where
- South Korea
- Volunteers
- 905 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Age-related Macular Degeneration, Coronary Artery Disease
Ranibizumab and the Risk of Arterial Thromboembolic Events
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events.
- Conditions
- Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders
- Trial name
- RATE (NCT01319188)
- Testing
- 0.5 mg of ranibizumab, 0.5 mg of ranibizumab + photodynamic therapy
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Ural State Medical University
Ulcerative Colitis (UC), Crohn's Diseases
Cardiovascular Risk in Patients With IBD
In this study the Research Hospital San Donato Policlinic ask the participation with the aim to evaluate the risk of cardiovascular complication (i.e. stroke, myocardial infarction) in patients with inflammatory bowel disease.
- Conditions
- Ulcerative Colitis (UC), Crohn's Diseases, Cardiovascular Risk
- Trial name
- DICOM-IBD (NCT07663201)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Acute Kidney Injury
Controlled Trial to Demonstrate a Reduction in the Number of Oliguria Events in Patients Being Managed in a Critical Care Unit, Following Cardiac Surgery, When a Novel Oliguria Prediction Tool (STABILITY UO) is Used to Identify Patients at Risk, Compared to Standard of Care.
Acute kidney injury (AKI) is experienced by 12% of patients following surgery and in up to 50% of patients following cardiac surgery.
- Trial name
- NCT05001503
- Testing
- Stability UO
- Where
- United Kingdom
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Rinicare Ltd
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prevention of Thromboembolic Events, Atrial Fibrillation
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: an irregular and often rapid heartbeat a blocked blood flow to the heart a blocked or reduced blood flow to a part…
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation, Acute Myocardial Infarction, Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05419635
- Testing
- Asundexian (BAY2433334)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
ST Elevation Myocardial Infarction (STEMI)
IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
This is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary…
- Trial name
- IMPROVE-STEMI (NCT07875179)
- Testing
- Recombinant Streptokinase
- Where
- China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Pneumonia, Pneumococcal, Myocardial Ischemia
Myocardial Injury and Severe Pneumococcal Pneumonia
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery…
- Trial name
- NEUMOCAR (NCT03058211)
- Testing
- Echocardiography, Cardiac Magnetic resonance
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Alejandro Rodriguez Oviedo , MD
Vaping, Electronic Cigarette Use
Vaping Adverse Lung and Heart Events Cohort
This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.
- Trial name
- VapALERT (NCT06291597)
- Testing
- Vaping
- Where
- Canada
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Laval University
Acute Coronary Syndrome, Myocardial Infarction
Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction
This is the continuation of previous study (registration number: NCT00844987) which revealed that hepatocyte growth factor (HGF) is a very early, good marker of myocardial injury and prognostic factor for post myocardial…
- Trial name
- NCT01233336
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Cardiology, Warsaw, Poland